Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months
2012-06-08 · Novo Nordisk A/S · original novonordisk.com ↗
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for the ultra-long-acting insulins degludec and insulin degludec/insulin aspart for the treatment of type 1 and type 2 diabetes. Further information: Media: Investors: Anne Margrethe Hauge Kasper Roseeuw Poulsen Tel: (+45) 4442 3450 Tel: (+45) 4442 4303 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ken Inchausti Jannick Lindegaard Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575 [email protected] [email protected] Company Announcement No 37 / 2012
The release as fetched from its publisher. novonordisk.com ↗